ClinicalTrials.gg
CompletedNCT04081610PRO-037Updated May 3, 2021Results posted

Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution

A Phase 1 interventional study of lagricel ofteno multidose and lagricel ofteno single dose in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.

Enrollment
16th of 18
34 · median 88
Started
2019
with 1 other
Phase 1
Only one
of the 18
Registered
9th of 18
by date
Lead sponsor
2 of 18
Laboratorios Sophia S.A de C.V.

Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1, and was the 9th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Study design: Phase I clinical trial, single-center, controlled, parallel group, open, randomized.

Number of subjects: n = 34 evaluable subjects, 17 evaluable subjects per group (both eyes).

Estimated duration of the study: 5 months

Therapeutic indication: Eye lubricant Use: Dry Eye

Objective:To evaluate the safety and tolerability of Lagricel® Ofteno multidose manufactured by Laboratorios Sophia on the ocular surface of clinically healthy subjects.

Hypothesis:

H0 = Lagricel® Ofteno multidose ophthalmic solution has a safety and tolerability profile similar to Lagricel® Ofteno single dose in healthy subjects.

H1 = Lagricel® Ofteno multidose ophthalmic solution has a different safety and tolerability profile than Lagricel® Ofteno single dose in healthy subjects.

Main inclusion criteria: Clinically healthy subjects

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Dry eye
  • eye lubricant
  • sodium hyaluronate
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be clinically healthy
  • To have the ability to voluntarily grant your signed
  • To have the willingness to comply with scheduled visits treatment plan and other study procedures
  • Women in reproductive age should ensure the continuation (initiated ≥ 30 days prior to the signing of the informed consent) to use a hormonal method or intrauterine device during the study period.
  • To have a better corrected visual acuity of 20/30 or better in both eyes.
  • To have vital signs in normal parameters.
  • To have an intraocular pressure between ≥10 and ≤ 21 mmHg.

Exclusion criteria

Exclusion Criteria:

  • To be user of ophthalmic topical products of any kind.
  • To be user of medicines, or herbal products, by any other route of administration.
  • In the case of women: being pregnant, breastfeeding or planning to get pregnant in the study period.
  • Having participated in clinical research studies 90 days prior to inclusion in this study.
  • Having previously participated in this same study.
  • To be a user of contact lenses and can not suspend their use during the study.
  • Having initiated the use of hormonal or intrauterine devices, 30 days prior to inclusion in the present study.
  • To have a history of any chronic degenerative disease.
  • Having inflammatory or infectious disease, active at the time of admission to the study.
  • Having injuries or unresolved injuries at the time of admission to the study.
  • Having a history of any type of eye surgery.
  • Having undergone surgical procedures, not ophthalmological, in the last 3 months.
  • To be or to have an immediate family member (for example: spouse, parent / legal guardian, brother or child) who is part of the research site staff or the sponsor who participates directly in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Lagricel® Ofteno Multidose

    Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia

    Drug: lagricel ofteno multidose

  • Active comparator
    Lagricel® Ofteno Single dose

    Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia

    Drug: lagricel ofteno single dose

Interventions

  • * Dosage: 1 drop 4 times a day per 7 days, both eyes * Route of administration: Ophthalmic

    Also known as: sodium hyaluronate 0.4%

  • * Dosage: 1 drop 4 times a day per 7 days, both eyes * Route of administration: Ophthalmic

    Also known as: sodium hyaluronate 0.4%

06

What researchers measure

Primary outcomes

  1. Presence of Adverse Events (AEs)

    the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

    Time frame: during the 10 days of evaluation, including the safety call (day 11).

  2. Eye Comfort Index (ECI)

    It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

Secondary outcomes

  1. Visual Acuity (VA)

    Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

  2. Epithelial Defects (ED) Fluorescein Stain

    The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

  3. Epithelial Defects (ED) Green Lissamine

    The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

  4. Conjunctival Hyperemia (CH)

    Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

  5. Chemosis

    It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening

    Time frame: will be evaluated at the end of the treatment (day 8, final visit)

07

Results

Posted May 3, 2021

Participant flow

Participant flow — Overall Study
MilestoneLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Started1618
Completed1618
Not completed00

Outcome measures

PrimaryPresence of Adverse Events (AEs)

the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent

Time frame:
during the 10 days of evaluation, including the safety call (day 11).
Reported as:
Count of participants · Participants
Presence of Adverse Events (AEs)
ParticipantsLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Presence of Adverse Events (AEs)78
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Wilcoxon (Mann-Whitney) · p = 0.409 · Median difference (final values): 0.05
PrimaryEye Comfort Index (ECI)

It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100).The Eye comfort index contains items that focus on the discomfort associated with alterations of the ocular surface.(0: None discomfort, 100: high discomfort).

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Mean · score on a scale
Eye Comfort Index (ECI)
score on a scaleLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Inicial ECI29.98 (20.31 to 39.66)27.28 (21.38 to 33.18)
Final ECI18.76 (12.31 to 25.21)18.01 (11.57 to 24.44)
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Wilcoxon (Mann-Whitney) · p = 0.442
  • Lagricel® Ofteno Multidose · Wilcoxon (Mann-Whitney) · p = 0.009
  • Lagricel® Ofteno Single Dose · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryVisual Acuity (VA)

Visual acuity (VA) is a test of visual function. It will be evaluated at baseline, without refractive correction with the Snellen chart.Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3meters from the subject to be evaluated. The snellen chart consists of a booklet with 11 lines composed of letters, each line has a different size and a different weighting. the subject is placed at a safe distance and the contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Mean · LogMAR
Visual Acuity (VA)
LogMARLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Final VA0.988 ± 0.050.989 ± 0.05
Initial VA0.969 ± 0.090.989 ± 0.05
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Wilcoxon (Mann-Whitney) · p = 0.904
  • Lagricel® Ofteno Multidose · Sign test · p = 0.157
  • Lagricel® Ofteno Single Dose · Sign test · p = 1.000
SecondaryEpithelial Defects (ED) Fluorescein Stain

The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Count of units · Eyes
Epithelial Defects (ED) Fluorescein Stain
EyesLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Final Fluorescein Staining Grade 03034
Final Fluorescein Staining Grade 122
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Fisher Exact · p = 1.000
  • Lagricel® Ofteno Multidose · Chi-squared · p = 0.041
  • Lagricel® Ofteno Single Dose · Chi-squared · p = 0.665
SecondaryEpithelial Defects (ED) Green Lissamine

The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Count of units · Eyes
Epithelial Defects (ED) Green Lissamine
EyesLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Final Lissamine Green Staining Grade 02931
Final Lissamine Green Staining Grade 135
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Fisher Exact · p = 0.713
  • Lagricel® Ofteno Multidose · Chi-squared · p = 0.002
  • Lagricel® Ofteno Single Dose · Chi-squared · p = 0.777
SecondaryConjunctival Hyperemia (CH)

Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as 0.-Normal / 1.-Very Light/ 2.- Light/ 3.-Mild / 4.-Moderate / 5.- Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Count of units · Eyes
Conjunctival Hyperemia (CH)
EyesLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Hyperemia grade 0 (Normal)3236
Hyperemia grade 1 (Very Light)00
Hyperemia grade 2 (Light)00
Hyperemia grade 3 (Mild)00
Hyperemia grade 4 (Moderate)00
Hyperemia grade 5 (Severe)00
Statistical analysis
  • Lagricel® Ofteno Multidose vs Lagricel® Ofteno Single Dose · Chi-squared, Corrected · p = 1.000
  • Lagricel® Ofteno Multidose · Fisher Exact · p = 0.031
  • Lagricel® Ofteno Single Dose · Chi-squared, Corrected · p = 1.000
SecondaryChemosis

It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if the conjunctiva separates from the sclera by ≥ 1/3 of the total eyelid opening

Time frame:
will be evaluated at the end of the treatment (day 8, final visit)
Reported as:
Count of units · Eyes
Chemosis
EyesLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
Final chemosis present00
Final chemosis absent3236

Adverse events

Collected over Adverse events were monitored throughout the study, which lasted about 1 month and 15 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lagricel® Ofteno Multidose0/16 (0%)0/16 (0%)7/16 (43.8%)
Lagricel® Ofteno Single Dose0/18 (0%)0/18 (0%)8/18 (44.4%)
Most frequent other events
Most frequent other events
EventLagricel® Ofteno MultidoseLagricel® Ofteno Single Dose
burning eyesEye disorders4/165/18
blurred visionEye disorders2/163/18
eye itchingEye disorders2/161/18
dysgeusiaGastrointestinal disorders1/162/18
foreign body sensationEye disorders0/162/18
TearingEye disorders1/160/18
HeadacheNervous system disorders1/161/18
Eye irritationEye disorders0/161/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lagricel® Ofteno MultidoseLagricel® Ofteno Single DoseTotal
Mean27.8 ± 6.629.7 ± 7.929.0 ± 7.33
Sex: Female, Male
Sex: Female, Male(Participants)Lagricel® Ofteno MultidoseLagricel® Ofteno Single DoseTotal
Female12921
Male4913
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Lagricel® Ofteno MultidoseLagricel® Ofteno Single DoseTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Lagricel® Ofteno MultidoseLagricel® Ofteno Single DoseTotal
Mexico161834
08

Study locations

1 site
  • Biomedical research G & LS de RL de CV
    Guadalajara, Jalisco 45070, Mexico
09

References and documents

Publications

  • Munoz-Villegas P, Navarro-Sanchez AA, Sanchez-Rios A, Olvera-Montano O, Baiza-Duran LM. Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials. Ther Clin Risk Manag. 2021 Oct 21;17:1123-1134. doi: 10.2147/TCRM.S331294. eCollection 2021. PubMed 34707360 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Laboratorios Sophia, S.A. de C.V., serving as the sponsor of the study, assumes full responsibility for its function and retains exclusive ownership rights over the results of the study. The principal investigator undertakes not to publish or communicate data collected from the study, unless there is prior written agreement of Laboratorios Sophia, S.A. de C.V.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Oct 2019, 1 month.

Results were first posted in May 2021, 1 year 6 months after primary completion.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 9, 2019
StartActual
Sep 9, 2019
Primary completionActual
Oct 23, 2019
CompletionActual
Nov 13, 2019
Results first posted
May 3, 2021
Last update
May 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04081610
Responsible party
Sponsor
First posted
Sep 9, 2019
Start date
Sep 9, 2019
Primary completion
Oct 23, 2019
Completion
Nov 13, 2019
Results posted
May 3, 2021
Last update
May 3, 2021

Study contacts

Leopoldo Baiza Durán, MD
study director · Laboratorios Sophia S.A de C.V.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion